Interview with Israel Garcia Crespo, General Manager, Almirall Mexico
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
Address: Periferico Sur 3325 Piso 1, Col. San Jeronimo Lidice, Mexico D.F.
,Mexico
Tel: +52 5 559 998 600
Web: http://www.almirall.com/webcorp2/cda/index.jsp
Almirall is an international pharmaceutical company with headquarters in Spain, based on innovation and committed to health, and develops, manufactures and commercializes its own Research & Development driven licensed drugs, with the aim of improving health and welfare of people. Currently, our drugs are marketed in over 70 countries including the USA and Japan, either through our own subsidiaries or through marketing agreements with renowned pharmaceutical companies. Almirall has 11 subsidiaries in Europe, including Spain, Germany, Austria, Belgium, France, Italy, Poland, Portugal, United Kingdom, Ireland and Switzerland and Mexico. Almirall S.A. de C.V.- the company’s only Latin American presence- began operating in 2000 with the aim of consolidating the company’s international expansion and entering placing its main strategic products into the Mexican market specifically.
Almirall S.A. de C.V. currently has 9 innovative products in the Mexican market in fields ranging from Dermatology to Oncology, which provide solutions to Mexican society in improving their quality of life and health.
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
Arturo Prida Romero, the president of the current National Council of the Partido de la Revolución Democrática (PRD) – one of the main political parties in Mexico – shares the…
Mario Muniz, SVP and GM of IQVIA North LATAM, shares his motivations for joining IQVIA after nearly two decades with pharma and medtech companies, the huge potential of the North…
Earlier in 2020, PharmaBoardroom sat down with several key stakeholders in the Mexican healthcare and life sciences industry, from the leaders of multinational affiliates, start-up entrepreneurs, association heads, and key…
Diego Ruiz, CEO and co-founder of Eseotr3s Pharma shares his entrepreneurial background and the motivation for establishing Eseotr3s Pharma; their focus on flexibility and quality; their international operations and network,…
Chiesi Mexico’s Marco Ruggiero discusses his initial impressions of the Mexican pharma market, his strategic priorities for the affiliate, and the increasing importance of the company’s respiratory portfolio in Mexico.…
Novartis Mexico Country President Fernando Cruz outlines the new normal for Mexican healthcare post-regulatory reform, how the company’s global reshuffle has impacted Mexican operations, and the challenges inherent in bringing…
David López García, Mexico country manager of global rare genetic therapy player Biomarin, outlines the challenging situation around patient access to orphan drugs in Mexico and the importance of building…
Dr David Kershenobich Stalnikowitz, director-general of the Salvador Zubirán National Institute of Medical Sciences and Nutrition (INCMNSZ) shares the many new initiatives the Institute has introduced in the past couple…
In the historic year of their 70th anniversary, Cristóbal Thompson, executive director of the Asociación Mexicana de Industrias de Investigación Farmacéutica (AMIIF), the association for research-based pharmaceutical companies in Mexico,…
Rafael Gual Cosío, director general of the Cámara Nacional de la Industria Farmacéutica (CANIFARMA), the umbrella industry association for the healthcare sector in Mexico, shares his perspectives on the complex…
The election of populist President Andres Manuel Lopez Obrador (AMLO) on 1 July 2018 heralded a new era of hope and optimism for Mexicans. In the first 13 months of…
Juan de Villafranca, executive director of the Asociacion Mexicana de Laboratorios Farmaceuticos (AMELAF), shares the exciting new initiatives he has launched in the past two years of his term; the…
See our Cookie Privacy Policy Here
